Company intelligence / Profile preview

Beijing Wista Pharma

Ownership: Private
Development stage: Commercial

Overview

Several products have received approval from China’s NMPA/SFDA. These include new formulations of L-Ornithine-L-Aspartate Infusion, Nafcillin Sodium for injection, and Olopatadine hydrochloride tablets. The company appears to focus primarily on late-stage development through regulatory approval of generic/innovative chemical entities rather than novel clinical candidates.

Therapeutic areas: GastroenterologyImmunologyInfectious Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Beijing Wista Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Wista Pharma.

Explore the full profile